Intravitreal Ranibizumab/ Lucentis (IVTL) injections in Glaucoma patients-Intraocular Pressure (IOP) elevation and the use of Anterior Chamber Paracentesis (ACP)
Open Access
- 1 February 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 1 (1), 033-041
- https://doi.org/10.29328/journal.hceo.1001005
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Structural and Functional Abnormalities of Retinal Ganglion Cells Measured In Vivo at the Onset of Optic Nerve Head Surface Change in Experimental GlaucomaInvestigative Ophthalmology & Visual Science, 2012
- Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agentsBritish Journal of Ophthalmology, 2010
- HIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMABRetina, 2010
- Short-term Effect of Intravitreal Injection of Ranibizumab (Lucentis) on Intraocular PressureJournal of Glaucoma, 2009
- Bevacizumab Local ComplicationsOphthalmology, 2009
- Short-term effect of intravitreal anti-VEGFs delivery on intraocular pressureBritish Journal of Ophthalmology, 2009
- Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complicationEye, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Nonarteritic anterior ischemic optic neuropathyCurrent Opinion in Opthalmology, 2002